Title :

The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.

Author(s) :

Maanaoui, Mehdi [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Chetboun, Mikael [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Top, Isabelle [Auteur]
Institut d'Immunologie [CHRU Lille]
Elsermans, Vincent [Auteur]
Institut d'Immunologie [CHRU Lille]
Pattou KERR-CONTE, Julie [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Le Mapihan, Kristell [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Defrance, Frederique [Auteur]
Recherche translationnelle sur le diabète - U 1190 [RTD]
Gmyr, Valery [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Hubert, Thomas [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Labalette, Myriam [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hazzan, Marc [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Vantyghem, Marie-Christine [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190
Pattou, Francois [Auteur]
Recherche translationnelle sur le diabète (RTD) - U1190

Journal title :

Scientific Reports

Abbreviated title :

Sci Rep

Volume number :

12

Pages :

12463

Publication date :

2022-07-24

ISSN :

2045-2322

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several ...
Show more >Islet transplantation is a unique paradigm in organ transplantation, since multiple donors are required to achieve complete insulin-independence. Preformed or de novo Donor Specific Antibodies (DSA) may target one or several donor islets, which adds complexity to the analysis of their impact. Adult patients with type 1 diabetes transplanted with pancreatic islets between 2005 and 2018 were included in a single-center observational study. Thirty-two recipients with available sera tested by solid-phase assays for anti-HLA antibodies during their whole follow-up were analyzed. Twenty-five recipients were islet-transplantation-alone recipients, and 7 islet-after-kidney recipients. Seven recipients presented with DSA at any time during follow-up (two with preformed DSA only, one with preformed and de novo DSA, 4 with de novo DSA only). Only islet-transplantation-alone recipients presented with de novo DSA. Three clinical trajectories were identified according to: 1/the presence of preformed DSA, 2/early de novo DSA or 3/late de novo DSA. Only late de novo DSA were associated with unfavorable outcomes, depicted by a decrease of the β-score. Islet transplantation with preformed DSA, even with high MFI values, is associated with favorable outcomes in our experience. On the contrary, de novo DSA, and especially late de novo DSA, may be associated with allograft loss.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• Recherche translationnelle sur le diabète (RTD) - U1190

Submission date :

2024-01-12T01:01:27Z
2024-01-26T09:30:03Z